유리체강 내 라니비주맙, 애플리버셉트주입술 후 안압상승에 대한 분석

• 영문명: Analysis of Intraocular Pressure Elevation after Intravitreal Injection of Ranibizumab and Aflibercept
• 발행기관: 대한안과학회
• 저자명: 문태규(Tae Kyu Moon) 하준영(Jun Young Ha) 성미선(Mi Sun Sung) 박상우(Sang Woo Park)
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume60,number4, 362~368쪽, 전체 7쪽
• 주제분류: 의약학 > 의학일반
• 파일형태: PDF
• 발행일자: 2019.04.30

영문 초록

Purpose: To evaluate long-term intraocular pressure (IOP) and risk of IOP elevation after intravitreal injection of ranibizumab or aflibercept in patients with age-related macular degeneration (AMD). Methods: From January 2013 to December 2016, we retrospectively reviewed patients who underwent intravitreal ranibizumab or aflibercept injections for AMD. IOP was measured before injection and 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, and 1 year after injection. Sustained IOP elevation was defined when the final IOP increased by 6 mmHg more than the pre-injection IOP, and when there were two consecutively measured values > 21 mmHg. The risk factors were then analyzed. Results: Using Kaplan-Meier survival analysis, sustained IOP elevation occurred in 9 of 80 eyes (11.3%) in 1 year, and the mean survival time was 11.50 months after injection. Five eyes (12.8%) of the ranibizumab group and four eyes (9.8%) of the aflibercept group had mean survival times of 11.39 and 11.61 months, respectively. The log-rank test showed no significant difference between the two groups (p = 0.659). A significant risk factor for sustained IOP elevation was a history of primary open-angle glaucoma (p = 0.035). Conclusions: The incidence of sustained IOP elevation was not significantly different between the two groups. Clinicians should therefore carefully monitor the IOP before and after intravitreal ranibizumab or aflibercept injections, especially in AMD patients with primary open-angle glaucoma. J Korean Ophthalmol Soc 2019;60(4):362-368

목차

대상과 방법

결 과

고 찰

REFERENCES

키워드

Aflibercept Intraocular pressure Intravitreal injection Ranibizumab